US Stock MarketDetailed Quotes
CUE Cue Biopharma
- 1.365
- -0.045-3.19%
Close Apr 26 16:00 ET
- 1.369
- +0.004+0.32%
Post 19:28 ET
66.40MMarket Cap-1229P/E (TTM)
1.440High1.315Low264.39KVolume1.400Open1.410Pre Close359.63KTurnover0.58%Turnover RatioLossP/E (Static)48.64MShares5.12052wk High1.79P/B61.94MFloat Cap1.30352wk Low--Dividend TTM45.38MShs Float31.690Historical High--Div YieldTTM8.87%Amplitude1.303Historical Low1.360Avg Price1Lot Size
Cue Biopharma Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 4.41%-39.96M | -4.22%-10.96M | -13.51%-7.8M | 19.28%-10.37M | 6.39%-10.83M | -7.64%-41.81M | 1.23%-10.51M | -3.68%-6.87M | -31.50%-12.85M | 1.88%-11.57M |
| Net income from continuing operations | 4.30%-50.73M | 7.94%-13.43M | -0.46%-11.01M | 0.17%-13.19M | 8.04%-13.11M | -20.04%-53.01M | -74.04%-14.59M | 15.69%-10.96M | -28.49%-13.21M | -13.99%-14.26M |
| Operating gains losses | 153.98%287K | -34.36%191K | 0.00%33K | --32K | --31K | 624.36%113K | 53,009.09%291K | 1,750.00%33K | ---- | ---- |
| Depreciation and amortization | 90.25%3.44M | 46.72%851K | 58.81%856K | 85.37%849K | 284.28%880K | 201.58%1.81M | 109.46%580K | -63.31%539K | -82.15%458K | -27.99%229K |
| Other non cash items | 115.04%37K | 103.37%9K | 11.11%10K | 0.00%9K | 200.00%9K | ---246K | ---267K | --9K | --9K | -99.73%3K |
| Change In working capital | -362.36%-934K | -140.90%-647K | -84.03%246K | 98.19%-40K | 12.12%-493K | 108.11%356K | 76.65%1.58M | -6.55%1.54M | 41.57%-2.21M | 82.23%-561K |
| -Change in receivables | -153.19%-1.64M | -105.15%-38K | -776.67%-526K | -596.30%-938K | -106.27%-139K | 278.84%3.09M | 131.13%738K | -105.30%-60K | 138.49%189K | 55,350.00%2.22M |
| -Change in prepaid assets | 106.93%25K | -76.14%210K | -32.30%746K | 134.38%448K | -32.60%-1.38M | -81.45%-361K | 23.07%880K | -42.60%1.1M | -4.91%-1.3M | 34.67%-1.04M |
| -Change in payables and accrued expense | 237.45%1.36M | -89.74%31K | 48.55%1.18M | 260.16%1.44M | -8.41%-1.29M | -141.99%-988K | -59.79%302K | -45.70%795K | -220.11%-896K | -95.56%-1.19M |
| -Change in other current liabilities | -279.32%-2.79M | -114.20%-724K | -139.06%-710K | -260.00%-702K | -786.32%-652K | -125.29%-735K | -105.27%-338K | 76.07%-297K | 83.75%-195K | 108.86%95K |
| -Change in other working capital | 427.44%2.11M | ---126K | ---445K | ---283K | 559.84%2.97M | 91.91%-645K | --0 | --0 | --0 | -364.03%-645K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 4.41%-39.96M | -4.22%-10.96M | -13.51%-7.8M | 19.28%-10.37M | 6.39%-10.83M | -7.64%-41.81M | 1.23%-10.51M | -3.68%-6.87M | -31.50%-12.85M | 1.88%-11.57M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 201.59%25M | 0 | 116.94%5M | 8,164.52%5M | 55,662.96%15M | -370.19%-24.61M | 978,177.89%5M | -268,263.64%-29.52M | 73.39%-62K | -100.29%-27K |
| Net PPE purchase and sale | 101.21%2K | --0 | --0 | --0 | 107.41%2K | 81.49%-165K | -295.69%-1K | -581.82%-75K | 73.39%-62K | 95.83%-27K |
| Net investment purchase and sale | 202.27%25M | --0 | 116.98%5M | --5M | --15M | -344.45%-24.45M | --5M | ---29.45M | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 201.59%25M | --0 | 116.94%5M | 8,164.52%5M | 55,662.96%15M | -370.19%-24.61M | 978,177.89%5M | -268,263.64%-29.52M | 73.39%-62K | -100.29%-27K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -77.90%11.86M | -82.55%4.78M | 51,088.89%4.59M | -81.09%2.1M | -97.44%388K | 178.99%53.66M | 271.20%27.4M | -102.56%-9K | 4.15%11.11M | 1,717.27%15.16M |
| Net issuance payments of debt | -120.00%-2M | ---1M | ---1M | --0 | --0 | --10M | --0 | --0 | --0 | --10M |
| Net common stock issuance | -65.94%13.39M | -74.53%5.78M | --5.59M | -81.85%2.02M | --0 | 126.06%39.3M | 223.04%22.7M | --0 | 7.26%11.11M | --5.49M |
| Proceeds from stock option exercised by employees | -89.94%473K | --0 | --0 | --85K | --388K | 80.85%4.7M | 773.96%4.7M | --0 | --0 | --0 |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | 54.54%-341K | 100.55%1K | 98.13%-9K | --0 | -291.76%-333K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -77.90%11.86M | -82.55%4.78M | 51,088.89%4.59M | -81.09%2.1M | -97.44%388K | 178.99%53.66M | 271.20%27.4M | -102.56%-9K | 4.15%11.11M | 1,717.27%15.16M |
| Net cash flow | ||||||||||
| Beginning cash position | -19.77%51.76M | 83.56%54.84M | -19.95%53.05M | -17.27%56.32M | -19.77%51.76M | -13.99%64.52M | -55.92%29.88M | -10.52%66.28M | -7.26%68.08M | -13.99%64.52M |
| Current changes in cash | 75.71%-3.1M | -128.22%-6.18M | 104.92%1.79M | -81.57%-3.27M | 28.15%4.56M | -21.55%-12.76M | 770.93%21.89M | -478.97%-36.4M | -371.64%-1.8M | 321.01%3.56M |
| End cash Position | -5.99%48.67M | -5.99%48.67M | 83.56%54.84M | -19.95%53.05M | -17.27%56.32M | -19.77%51.76M | -19.77%51.76M | -55.92%29.88M | -10.52%66.28M | -7.26%68.08M |
| Free cash flow | 4.80%-39.96M | -4.21%-10.96M | -12.23%-7.8M | 19.69%-10.37M | 6.61%-10.83M | -5.60%-41.98M | 1.22%-10.52M | -4.65%-6.95M | -28.85%-12.91M | 6.77%-11.6M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg